| Literature DB >> 27662508 |
Carl Rudolf Blankart1, Ricarda Milstein1, Meike Rybczynski2, Helke Schüler2, Yskert von Kodolitsch2.
Abstract
INTRODUCTION: Marfan syndrome is a rare multisystem disease of the connective tissue, which affects multiple organ systems. advances in healthcare have doubled the life-expectancy of patients over the past three decades. to date, there is no comprehensive review that consolidates economic considerations and care for marfan patients. Areas covered: Present research suggests that there may be a link between treatment pattern, disease progression and economic costs of Marfan syndrome. It indicates that an early detection of the disease and preventive interventions achieve a dual aim. From a patient perspective, it may reduce the amount of emergency surgery or intervention, and inpatient stays. In addition, it slows disease progression, lowers lifestyle restrictions, reduces psychological stress, and improves health-related quality of life. Expert commentary: Early detection and preventive measures are likely to achieve a dual aim by simultaneously containing costs and reducing the number and length of inpatient stays.Entities:
Keywords: FBN1; Loeys-Dietz syndrome; Marfan syndrome; TGFBR2; costs; decision-making; economy; gene; healthcare; surgery
Mesh:
Year: 2016 PMID: 27662508 DOI: 10.1080/14737167.2016.1240619
Source DB: PubMed Journal: Expert Rev Pharmacoecon Outcomes Res ISSN: 1473-7167 Impact factor: 2.217